November 15, 2019 8:22am

So inhale, don’t exhale, when the market moves, breathe deeper

Take another toke of momentum to motivate the superficial sentiment

As the oversold needs to light-up volume

RMi outlines the potential prelude to the daily dosage of facts and objectivity!

 

My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline – which are?

 

Dow futures are UP +0.28% (+78 points), S&P futures are UP +0.25% (+8 points) and NASDAQ futures are UP +0.37% (+31 points)

 

U.S. stock index futures were higher Friday morning;

European stocks traded mixed; the pan-European Stoxx 600 slipped 0.15% below the flat line by late morning, dragged down by a 0.6% decline for Britain’s FTSE 100. Household goods slid 0.7% to lead losses while autos edged 0.3% higher;

Asia Pacific stocks mostly higher as investors digest US-China trade developments

 

Data Docket: There will be retail sales, import prices and the Empire State manufacturing numbers out at 08:30 a.m. ET.  Investors will also be waiting for the release of the Federal Reserve Financial Stability report due at 2:00 p.m. ET.

 

Henry’omics:

Go with the flow, the machine algorithms are setting the pace for trading …

Spits and spurts are the theme of today’s sector activity!

 

Thursday night’s newsletter heading: “four (4) flopping sessions in a row for my comparable universe. Zombie (equities) is my sentiment term for a sector considered to lack vitality, interest and a volume pulse.”

Last night’s closing numbers:

  • The NASDAQ closed DOWN -3.08 points (-0.04%)
  • The IBB closed down -0.72% while the XBI closed down -0.59%
  • The close was negative with an A/D line of 17/25, 0 flat, 1 reversed merged (HSGX) and 2 acquired;
  • The range of the 17 upside was +0.11% (CRSP) to +12.63% (BLCM) while the  25 downside ranged from -0.11% (STML) to -16.94% (CUR);
  • 4 out of the 17 upside had higher than the 3 month average volume;
  • 5 out of the 25 downside had higher than the 3 month average volume;

Review the context of Q4’s market – so far:

  • November has registered 4 positive and 6 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

 I’m looking at SELLING:

CRISPR Therapeutics (CRSP +$0.06 after Wednesday’s +$0.21, Tuesday’s +$2.67, Monday’s +$0.37, Friday’s +$1.53, Thursday’s +$1.18 and last Wednesday’s +$1.23 – a lot of upside that could be sold into;

AxoGen (AXGN) which closed up +$0.37 - take some off the table;

Homology Medicine (FIXX) which closed up +$1.24 and has been on a “tear” - take some off the table;

ThermoGenesis Holdings (KOOL) closed up +$0.35 – don’t trust is …

 

Considering BUYING: the oversold …

bluebird bio (BLUE) closed down -$3.04

Sage Therapeutics (SAGE) closed down -$3.26;

Voyager therapeutics (VYGR) closed down -$1.16

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.